
|Articles|December 15, 2002
Novartis Transfers Apligraf
Boston - Although officials are mum on details, product quality appears to be one factor in the transfer of worldwide marketing of Apligraf from Novartis Inc. back to Organogenesis, which develops the engineered skin and is solely responsible for its manufacture.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














